Model designation GSH-R-PH-01, L-Glutathione Reduced Pharma Grade API, is released as a white to off-white crystalline powder conforming to the current European Pharmacopoeia monograph for glutathione and the corresponding USP/NF monograph where applicable. The chemical entity is (2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoic acid, CAS 70-18-8, EC 200-725-4, linear formula C₁₀H₁₇N₃O₆S, molar mass 307.32 g/mol. The material is controlled as the reduced thiol form rather than the oxidized disulfide dimer. Pharmacopoeial assay acceptance is 98.0–101.0% on the dried basis by HPLC with UV detection at 210 nm. Specific optical rotation is specified as −15.5° to −17.5° at 20 °C using the sodium D line. The powder is freely soluble in water, very slightly soluble in ethanol, and practically insoluble in dichloromethane. This solubility profile supports aqueous granulation and parenteral compounding but limits direct use in non-aqueous lipid-based systems. The product is intended for oral tablet, capsule, and granule manufacture and for injection after further bioburden and endotoxin control; it is not a sterile API as released.

Prior to use in oral solid-dosage or injectable manufacture, batch release documentation should be reviewed for ICH Q3C residual solvent certification, ICH Q3D elemental impurity risk assessment, and Ph. Eur. 2.6.12 and 2.6.13 microbiological enumeration. For oral solid dosage forms, the non-sterile API is acceptable; for injectable applications, the same synthesis intermediate is further processed through bioburden reduction and endotoxin control. Storage at 2–8 °C in sealed, light-resistant containers under nitrogen is required. An opened container at 25 °C and 60% relative humidity may show measurable oxidation to GSSG within 72 h; therefore, handling is performed in humidity-controlled suites below 60% RH with nitrogen overlay.

Why Is the Reduced Sulfhydryl State the Primary Specification Risk?

The free thiol group of L-glutathione reacts with trace transition metals and dissolved oxygen; the resulting disulfide dimer, L-glutathione oxidized, is the key related substance. In aqueous solution at pH 7.4, thiol oxidation is rapid under aerobic conditions, and the rate increases with iron(III) contamination. The reduced product is isolated under nitrogen, and recrystallization water is treated with citric acid at 0.01–0.05% w/v and degassed to maintain dissolved oxygen below 0.1 mg/L. Vacuum drying is performed below 10 kPa at jacket temperature not exceeding 40 °C. Loss on drying is measured at 60 °C for 3 h under vacuum with acceptance ≤0.5%, using Ph. Eur. 2.2.32 or USP <731>. Related substances by HPLC control oxidized glutathione at ≤0.5%, any unspecified impurity at ≤0.10%, and total impurities at ≤1.0%. Sulfated ash is limited to ≤0.1%, translating to inorganic residue below 1 mg/g. Heavy metals are screened by Ph. Eur. 2.4.8 or USP <231>, with ICH Q3D element-specific data replacing non-specific wet-chemical tests where the risk assessment requires. The API is packaged in double polyethylene bags inside aluminum foil laminate under nitrogen; unopened shelf life is assigned based on long-term data at 2–8 °C, and any deviation to room-temperature storage must be supported by stability protocols.

For assay and related substance analysis, a stability-indicating HPLC method uses a 250 mm × 4.6 mm, 5 µm octadecylsilyl column with phosphate buffer pH 3.0 and acetonitrile in a 95:5 ratio. The mobile phase is delivered at 1.0 mL/min, column temperature is 25 °C, and UV detection is set at 210 nm. System suitability requires resolution between GSH and GSSG of not less than 2.0 and a GSH tailing factor not more than 2.0. GSSG elutes at a relative retention time of approximately 1.2 under these conditions. The method is capable of separating other process-related impurities, and quantification of the reduced form avoids overestimation that may occur with non-specific iodometric titration when residual thiol-containing impurities are present.

For tablet and capsule processing, the raw API typically exhibits a bulk density around 0.35 g/mL and tapped density near 0.55 g/mL, giving a Carr index above 30% and Hausner ratio above 1.4. These values, obtained by USP <616>, indicate poor flow and make direct compression unsuitable for high-dose formulations containing more than 50 mg active per unit. Pre-drying at 45 °C under vacuum below 10 kPa lowers moisture below 0.5% before dry granulation. Roller compaction is evaluated for ribbons with force ranges from 5 kN/cm to 15 kN/cm depending ribbon density; a screen size of 1.0 mm yields granules that blend with microcrystalline cellulose and croscarmellose sodium. In high-shear wet granulation, an aqueous povidone K30 binder solution at 2–5% w/v is added, and the bowl temperature is kept below 35 °C to limit thiol oxidation. The granulation is dried under vacuum at 40 °C. Tablet compression using a rotary press with 8.0 mm round tooling and compression force 10–15 kN produces compacts with hardness 60–100 N and friability below 0.5% per USP <1216>. Capsule filling with an automatic capsule filler uses tamping pin penetration 10–15 mm; blend uniformity acceptance is 90.0–110.0% of label claim with RSD ≤5.0% per USP <905>. Dissolution testing in deaerated water at 37 °C using USP apparatus II at 50 rpm typically releases more than 80% in 30 min for immediate-release granules; modified-release configurations require separate validation because published data for this specific API in extended-release matrices is limited.

For oral granules, dry granulation is preferred when the API load exceeds 100 mg per sachet because wet granulation increases aqueous contact time and can raise GSSG levels. When an aqueous granulation process is unavoidable, the binder solution is deaerated with nitrogen, and the wet mass is transferred to a vacuum dryer within 30 min to limit oxidation. Granule moisture is controlled to 0.3–0.8% for capsule filling and 0.5–1.0% for sachet filling. Blends containing mannitol and pregelatinized starch show less thiol loss than blends containing dibasic calcium phosphate dihydrate, which can release surface water at elevated drying temperatures. The choice of lubricant is limited to magnesium stearate at 0.5–1.0% w/w; hydrogenated vegetable oil and sodium stearyl fumarate are evaluated only after compatibility testing because of potential oxidative effects.

Injectable-Grade Endotoxin, Bioburden, and Sterile Filtration Boundaries

For injectable manufacture, the API is non-sterile and must meet a defined bioburden and bacterial endotoxin acceptance criterion. The finished-product endotoxin limit is calculated according to Ph. Eur. 2.6.14 or USP <85>. At the parenteral limit of 5 EU/kg/h, a 70 kg adult receiving 600 mg by intravenous infusion has a threshold of 0.58 EU/mg; a tighter API criterion of ≤0.10 EU/mg is commonly applied to permit combination products and pediatric dosing. Aseptic preparation uses a 0.22 µm polyethersulfone filter, nitrogen overlay, and disodium edetate at 0.01–0.05% w/v to stabilize the thiol group. The final aqueous solution is adjusted to pH 3.0–4.5, because alkaline conditions accelerate oxidation. Terminal sterilization by moist heat may increase GSSG if oxygen is not excluded, so aseptic filtration is preferred. Particulate matter is tested according to Ph. Eur. 2.9.19 or USP <788>; small-volume parenterals must meet not more than 6000 particles per container ≥10 µm and 600 particles per container ≥25 µm. Sterility testing follows Ph. Eur. 2.6.1 or USP <71>. ICH Q3D elemental impurity limits for parenteral administration require arsenic not more than 15 µg/day, cadmium 2 µg/day, lead 5 µg/day, and mercury 3 µg/day. Compatibility with elastomeric closures and silicone tubing must be verified because the free sulfhydryl group can react with sulfur-containing leachables.

For solution holding periods, refrigeration at 2–8 °C with nitrogen overlay is used; at pH 3.0–4.5, sulfhydryl oxidation is slower than at neutral pH. If the pH is adjusted above 6.0, dissolved oxygen accelerates oxidation even at reduced temperature. The final injectable solution is brought to physiological osmolality using sodium chloride or mannitol, and the osmolality is measured by freezing-point depression according to USP <785>. The product should not be compounded with transition-metal-containing diluents unless a chelating agent is included; published data for compatibility with total parenteral nutrition admixtures is limited.

When Is Oxidized Glutathione or a Protected Derivative Required Instead?

Reduced L-glutathione is selected when the free sulfhydryl group is required for antioxidant action or enzymatic conjugation. L-glutathione oxidized, molar mass 612.63 g/mol, contains a disulfide bridge and cannot be directly substituted for the reduced form in redox-based formulations; it may serve as a substrate in glutathione reductase assays but must be reduced intracellularly to the thiol. S-Acetyl-L-glutathione is investigated for oral delivery because the acetyl protecting group may reduce presepithelial degradation by intestinal γ-glutamyltransferase. This derivative is not covered by the reduced glutathione monograph, and the supplier must provide a separate impurity profile and release specification. Liposomal glutathione is a formulation technology that does not change the underlying API specification for identity, assay, related substances, residual solvents, and elemental impurities. Food and cosmetic grades of glutathione are not appropriate for pharmaceutical manufacture because their residual solvent, heavy metal, and microbiological controls may not meet ICH Q3C, ICH Q3D, and Ph. Eur. general texts. The reduced API is also differentiated by specific optical rotation −15.5° to −17.5° and by an oxidized glutathione impurity limit of ≤0.5%, which are not typical acceptance criteria for technical-grade material. In oral solid-dose formulations, iron oxide pigments and other transition-metal excipients should be avoided unless a chelating agent is present; the disulfide form does not carry the same free-thiol restriction, but it lacks equivalent reducing capacity.

L-Glutathione reduced as the free acid should not be confused with the sodium salt form used in some injectable compounding kits. Sodium content influences osmolality and pH; for the free acid, pH of a 10% aqueous solution is typically 5.0–6.0, and sodium hydroxide is added separately if neutralization is required. The free acid also differs from oxidized glutathione in reducing capacity and from S-acetyl-L-glutathione in pre-epithelial degradation profile. When a sodium salt is used, the stoichiometric correction for assay and sodium content must be documented on the release certificate.

Cleaning validation for manufacturing equipment is based on the aqueous solubility of the API. Purified water at 40 °C is used as the first rinse solvent, followed by a swab sampling procedure with HPLC quantitation. Acceptance limits are derived from maximum allowable carryover using ICH Q3C and a permitted daily exposure not exceeding 1/1000 of the lowest clinical dose. Dedicated or campaign manufacturing is recommended when alternating with highly potent or oxidation-sensitive products because the free thiol can bind to stainless steel surfaces and form residues that require alkaline cleaning.